Pharmacology & Pharmacy, 2013, 4, 573-577 Published Online November 2013 (http://www.scirp.org/journal/pp) http://dx.doi.org/10.4236/pp.2013.48082 Open Access PP 573 Statins and Sepsis Literature Review Alicia Hernández Torres1, Ana Belén Hernández Cascales2, Pedro Pujante Alarcón2, Alfonso López Ruiz3, María Ángeles Ibáñez Gil4, María Dolores Hellín Gil2 1Hospital University Virgen de la Arrixaca de Murcia, Murcia, Spain; 2Hospital University Virgen de la Arrixaca de Murcia, Murcia, Spain; 3Pharmaceutical Care Research at the University of Granada, Granada, Spain; 4Health Center Mariano Yago, Murcia, Spain. Email: lablilly@gmail.com Received September 8th, 2013; revised October 12th, 2013; accepted October 21st, 2013 Copyright © 2013 Alicia Hernández Torres et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. ABSTRACT Recent data suggest that, in addition to improving dyslipidemia, statin may reduce the risk of infections and infection- related complications. The aim of this study is to make a review of the literature about the effects of statins on clinically relevant outcomes of patients admitted to the hospital and having an infection and/or sepsis, principally in terms of in- tensive care unit admissions and related death. Keywords: Statins; Pravastatin; Simvastatin; Sepsis; Bacteremia; Mortality 1. Introduction The hallmark of sepsis syndrome is an intense inflam- matory response, which reflects a delicate interaction between the extensive activation of host defense mecha- nisms and direct and indirect effects of the invading mi- croorganisms and their toxins. As a result, a number of important abnormalities occur during sepsis, including endothelial dysfunction and apoptosis, activation and increased production of cytokines and other proinflam- matory mediators, activation and extravascular transmi- gration of leukocytes, and activation of platelets and co- agulation and complement systems [1-3]. For this reason, because numerous cascades are triggered during sepsis, selective blocking of inflammatory mediators may be insufficient to arrest this process [4]. Recent studies have demonstrated a wide variety of statin properties independent of their lipid-lowering abil- ity [5-8]. Statins inhibit 3-hydroxy-3 methylgutaryl co- enzyme A (HMG CoA) reductase, were developed as lipid level-lowering agents, and have been studied exten- sively in relation to atherosclerosis. However, statins not only reduce cholesterol level but also decrease the levels of intermediate products of cholesterol synthesis, princi- pally mevalonate, precursor of a lot of isoprenoids which play a crucial role in several intracellular signaling path- ways in inflammatory response. Apparently, this effect is the major explanation for the observed pleiotropic effects of statins, which include the modulation of both innate and adaptative immune system, antiinflammatory effects, the direct activation of heme oxygenase, direct interfer- ence in leucocyte-endothelial interactions, with limita- tions of the activation of endothelial cells and improve- ment of endothelial function, up-regulation of endothelial nitric oxide synthase and direct inhibition of major his- tocompatibility complex class II (MHCII), counteraction of the deleterious effects of sepsis on the coagulation system by inhibiting tissue factor expression and reduc- ing prothrombin fragment levels and by strongly increas- ing the expression of thrombomodulin [9-12]. Moreover, they have direct effects on pathogenic microorganisms, such as Salmonella typhimurium, HIV, CMV ordifferent fungi species [13-15]. Such anti-inflamatory, antioxidant, inmunomodulatory, and antiapoptotic features have been collectively referred to as pleiotropic effects [4]. 2. Effects of the Use of Statins in Sepsis Markers All of us known the effect of the statins in the reduction of pro-inflammatory cytoquines, as have been demon- strated in a randomized and prospective study comparing simvastatin to placebo, where there was a significant reduction in tumor necrosis factor alpha (TNF-α) and interleukin 6 (IL-6) in the statin group [16]. The same effect was demonstrated with atorvastatin in a study with septic rats; it showed that atorvastatin improves survival in septic rats, decreases circulating inflammatory cyto-
Statins and Sepsis Literature Review 574 kines, attenuating higher levels of IL-6 and TNF-α, and improves insulin resistance. If we take into account that, in septic patients, insulin resistance is accompanied by a reduction in the insulin-induced Akt (proteína kinase B) phosphorylation in liver, muscle and adipose tissue, and that this protein plays an important role in the protection against apoptosis, it is possible that the reduced insulin signaling through this pathway, in sepsis, may contribute to multiorgan failure by preventing or delaying apoptosis [17]. It seems that statins can have a protector activity in yeast sepsis; we know that yeast use the same HMG CoA reductase as humans, however, their end-product is er- gosterol rather than colesterol [18]; probably, this is the explanation of why simvastatin inhibit the growth of dif- ferent species of Candida [19], independently of the ef- fect in the reduction of pro-inflammatory cytokines. The population-based cohort study performed by Thomsen et al. C-reactive protein levels at admisión tended to be lower in statin users than in non users, perhaps because of the antiinflammatory effects of statins [20]. 3. Clinical Effect s of Statins in Sepsis Many, but not all studies, have demonstrated the benefits of statins in patients with sepsis [21]. Liappis et al. dem- onstrated that patients on statins had greater than 7 times greater chance of survival with sepsis [22]. Almog et al. showed in an ICU that only 2.4% of patients on a statin developed bacterial sepsis compared with 19% (p < 0.001) who were no at statin [23]. Gupta et al. also found that hemodiálisis patients taking statins were also sig- nificantly less likely to be hospitalizad for severe sepsis [24], and Van de Garde et al. showed a significant reduc- tion of the risk of pneumonia among patients with diabe- tes mellitus [25]. Kruger et al. studied a cohort of bac- teriemic patients and found a significantly lower inci- dence of mortality and bacteraemia-related mortality with statin therapy [26]. There have been several other retrospective observational studies with similar findings with bacteremia. Also, statins reduce the risk of nosoco- mial sepsis among patients hospitalized for acute coro- nary syndrome, ischemic stroke, or revascularization [27], and the risk of infection-related mortality among patients with atherosclerotic disease [28]. Furthermore, in pa- tients with sepsis [29], bacteremia [30] or community- acquired pneumonia [31] and in patients admitted to the intensive care unit with Acute Physiology and Chronic Health Evaluation II scores of ≥20 [32], statins prevented sepsis from becoming severe or decreased 28-day, 30- day, or 31 - 180-day mortality, hospital mortality, or bacteremia-related mortality. Al Harbi et al. found that statin therapy in critically ill patiens (specially those eld- erly, diabetics, patient with higuer severity of illness, with a low GCS, with several sepsis or with simvastatin) had a lower hospital mortality [33]. Statins also improved mortality among patients with angiographically defined coronary artery stenosis >70% and with concurrent cy- tomegalovirus seroposivity and high C-reactive protein levels. Patiens who received statins had a lower risk of death due to influenza, pneumonia, or chronic obstructive pulmonary disease in one study [34] and a lower risk of fatal pneumonia in another study [35]. In another hand, in a study which compared the outcomes of inmunocom- promised patients who received or not statins, the prior use of them was not associated with an increase of the survival [36]. Other investigations haven’t demonstrated benefits with statins in patients with sepsis, as Fernandez et al., who found that the hospital mortality was even higher in patients receiving statins and mechanical venti- lation [37], or Yang et al. [38] who conducted a retro- spective study and found no differences in mortality be- tween the two groups. However, Kopterides et al., in a critical review of 22 studies with 177,260 patients (7 prospective cohorts, 12 retrospective cohorts and 1 alea- torized clinic assay), concluded that the majority of stud- ies show that statins have a beneficial effect over the result of the infection; nevertheless, its observational design don’t let us to get firm conclusions [39]. Similar effects have been demonstrated with candidi- asis. The beneficial effect in the reduction of mortality in patients admitted to an ICU with candidemia associated to a systemic inflammatory response syndrome, was de- monstrated in the study performed by Forrest et al. [40], although the reduction in mortality wasn’t statistically significant in the multivariant analysis. In this study, the reduction of the inflammatory response in comparation with the control group, is probably due to the effects of statins in the production of cytokines and ergosterol. Evaluating the effects of statins in sepsis caused by concrete microorganisms, we can observe how, in a cli- nical study, patients who received statins had signifi- cantly lower overall and attributable mortality associated with bacteremic infections caused by gram-negative ba- cilli and S. aureus than did those not receiving statins. Simvastatin demonstrated a statistically significant an- timicrobial effect against methicillin-susceptible S. au- reus and, to a lesser extent, against methicillin-resistant S. aureus. Fluvastatin also showed a statistically significant but less marked antimicrobial effect, compared with that of simvastatin. Moreover, fluvastatin might have a po- tential role in the treatment of tuberculosis as a result of the enhacement of the host T-helper response agaisnt M. tuberculosis. In relation to fungi, we can see that statins show antifungal activity against Candida species; they inhibit the growth of Candida by decreasing the ergos- terol levels. It seems that lovastatin with fluconazole and fluvastatin with fluconazole or itraconazole had synergis- tic effects on Candida species, whereas pravastatin or fluvastatin with fluconazol haven’t demonstrated these Open Access PP
Statins and Sepsis Literature Review 575 effects. The combination of amphotericin B and fluvas- tatin had additive effects, too. Different statins have demonstrated activity against zygomycetes, Aspergillus, C. neoformans, or viruses as cytomegalovirus, Epstein- Barr virus or HIV [41]. 4. Are Statins Indicated in the Treatment of Septic Patients? The timing of initiation of statins with regards to the on- set of sepsis is still being determined. This is because it takes several days for statins to achieve desiderable con- centrations [42]. Moreover, the majority of patients who are statin-users don’t receive statins after the admission, because of the lack of intravenous formulation, although recent data suggest that this method may lead to elevated plasma levels of the statins [43]. Pre-admission use of a statin has shown relative risk reductions in large cohort studies evaluating community acquired pneumonia and ICU admission [20,44]. Thomsen et al. showed that the use of preadmisión statin up to 180 days prior to admis- sion demonstrated a 25% - 30% mortality rate reduction at 90 days [20]. Also, Christensen et al. showed about a 20% mortality rate reduction between statin users and non users [44]. However, Majumdar et al. showed in a prospective cohort study for pneumonia that the benefit of statins disappeared after adjustment for confounders [45]. We will need, because of all these reasons, more exhaustive studies to be able to make conclusions. 5. Conclusion Our review suggests that statin use is associated with a beneficial effect in treating and preventing different in- fections. Further studies are warranted to define the op- timal dose of statin and timing of therapy in a prospec- tive manner. REFERENCES [1] J. C. Marshall, “Sepsis: Current Status, Future Prospects,” Current Opinion in Critical Care, Vol. 10, No. 4, 2004, pp. 250-264. http://dx.doi.org/10.1097/01.ccx.0000134877.60312.f3 [2] M. Terblanche, Y. Almog, R. S. Ronsenson, T. S. Smith and D. G. Hackam, “Statin: Panacea for Sepsis?” Lancet Infectious Diseases, Vol. 6, No. 4, 2006, pp. 242-248. http://dx.doi.org/10.1016/S1473-3099(06)70439-X [3] I. M. Tleyjeh, T. Kashour, F. A. Hakim and V. A. Zim- merman, P. J. Erwin, et al., “Statins for the Prevention and Treatment of Infections. A Systematic Review and Meta-Analysis,” Archives of Internal Medicine, Vol. 169, No. 18, 2009, pp. 1658-1667. http://dx.doi.org/10.1001/archinternmed.2009.286 [4] I. Kouroumichakis, N. Papanas, S. Proikaki, P. Zaro- goulidis and E. Maltezos, “Statins in Prevention and Treatment of Severe Sepsis and Septic Shock,” European Journal of Internal Medicine, Vol. 22, No. 2, 2011, pp. 125-133. http://dx.doi.org/10.1016/j.ejim.2010.12.004 [5] G. Weitz-Schmidt, “Statins as Anti-Inflammatory Agents,” Trends in Pharmacological Sciences, Vol. 23, No. 10, 2002, pp. 482-486. http://dx.doi.org/10.1016/S0165-6147(02)02077-1 [6] L. M. Blanco-Colio, J. Tunon, J. L. Martin-Ventura and J. Egido, “Antiinflammatory and Inmunomoduladory Ef- fects of Statins,” Kidney International, Vol. 63, 2003, pp. 12-23. http://dx.doi.org/10.1046/j.1523-1755.2003.00744.x [7] M. Terblanche, Y. Almog, R. S. Rosenson, T. S. Smith and D. G. Hackman, “Statins and Sepsis: Multiple Modi- fications at Multiple Levels,” Lancet Infectious Diseases, Vol. 7, No. 5, 2007, pp. 358-368. http://dx.doi.org/10.1016/S1473-3099(07)70111-1 [8] C. P. Martin, R. L. Talbert, D. S. Burgess and J. I. Peters, “Effectiveness of Statins in Reducing the Rate of Severe Sepsis: A Retrospective Evaluation,” Pharmacotherapy, Vol. 27, No. 1, 2007, pp. 20-26. [9] B. Zingarelli, “Nuclear Factor-Kappa B,” Critical Care Medicine, Vol. 33, No. 12, 2005, pp. s414-s416. http://dx.doi.org/10.1097/01.CCM.0000186079.88909.94 [10] M. E. Falagas, C. G. Makris, D. K. Mstthaiou and P. I. Rafailidis, “Statins for Infection and Sepsis: A Systematic Review of the Clinical Evidence,” Journal of Antimicro- bial Chemotherapy, Vol. 61, No. 4, 2008, pp. 774-785. http://dx.doi.org/10.1093/jac/dkn019 [11] L. Kronmann, C. Hatfield and K. Kronmann, “Statin Therapy: Not Just Used to Lower Cholesterol?” Critical Care Nurse, Vol. 30, No. 2, 2007, pp. 154-160. [12] S. Steiner, W. S. Speidl, J. Pleiner, et al., “Simvastatin Blunts Endotoxin-Induced Tissue Factor in Vivo,” Circu- lation, Vol. 111, No. 14, 2005, pp. 1841-1846. http://dx.doi.org/10.1161/01.CIR.0000158665.27783.0C [13] G. Del Real, S. Jiménez-Baranda, E. Mira, et al., “Statins Inhibit HIV Infection by Down-Regulating Rho Activ- ity,” Journal of Experimental Medicine, Vol. 200, No. 4, 2004, pp. 541-547. http://dx.doi.org/10.1084/jem.20040061 [14] M. W. Merx, E. A. Liehn, U. Janssens, et al., “HMG- CoA Reductase Inhibitor Simvastatin Profoundly Im- proves Survival in a Murine Modelo Os Sepsis,” Circula- tion, Vol. 109, No. 21, 2004, pp. 2560-2565. http://dx.doi.org/10.1161/01.CIR.0000129774.09737.5B [15] A. Gyetvai, T. Emri, K. Takács, et al., “Lovastatin Po- sesses a Fungistatic Effect against Candida albicans, but Does Not Trigger Apoptosis in This Opportunistic Hu- man Patogen,” FEMS Yeast Research, Vol. 6, No. 8, 2006, pp. 1140-1148. http://dx.doi.org/10.1111/j.1567-1364.2006.00097.x [16] V. Novack, M. Eisinger, A. Frenkel, M. Terblanche, N. K. Adhikari, et al., “The Effects of Statins Therapy on In- flammatory Cytokines in Patients with Bacterial Infec- tions: A Randomized Double-Blind Placebo Controlled Clinical Trial,” Intensive Care Medicine, Vol. 35, No. 7, 2009, pp. 1255-1260. http://dx.doi.org/10.1007/s00134-009-1429-0 [17] K. L. Calisto, B. de Melo Carvalho, E. R. Ropelle, F. C. Open Access PP
Statins and Sepsis Literature Review 576 Mittestainer, A. C. A. Camacho, et al., “Atorvastatin Im- proves Survival in Septic Rats: Effect on Tissue Inflam- matory Pathway and on Insulina Signaling,” PloS One, Vol. 5, No. 12, 2010, Article ID: e14232. http://dx.doi.org/10.1371/journal.pone.0014232 [18] I. G. Macreadi, G. Johnson, T. Schlosser and P. I. Macreadi, “Growth Inhibition of Candida Species and Aspergillus fumigatus by Statins,” FEMS Microbiology Letters, Vol. 262, No. 1, 2006, pp. 9-13. http://dx.doi.org/10.1111/j.1574-6968.2006.00370.x [19] C. Westermeyer and I. G. Macreadi, “Simvastatin Re- duces Ergosterol Levels, Inhibits Growth and Causes Loss of mtDNA in Candida glabrata,” FEMS Yeast Re- search, Vol. 7, No. 3, 2007, pp. 436-441. http://dx.doi.org/10.1111/j.1567-1364.2006.00194.x [20] R. W. Thomsen, A. Riss, J. B. Kornum, S. Christensen, S. P. Johnsen, et al., “Preadmission Use of Statins and Out- comes after Hospitalization with Pneumonia,” Archives of Internal Medicine, Vol. 168, No. 19, 2008, pp. 2081-2087. http://dx.doi.org/10.1001/archinte.168.19.2081 [21] G. Mells and J. Neuberger, “Reducing the Risks of Car- diovascular Disease in Liver Allograft Recipients,” Trans- plantation, Vol. 83, No. 9, 2007, pp. 1141-1150. http://dx.doi.org/10.1097/01.tp.0000262706.28513.6a [22] A. P. Liappis, V. L. Kan, C. G. Rochester and G. L. Simon, “The Effect of Statins on Mortality in Patients with Bacteremia,” Clinical Infectious Diseases, Vol. 33, No. 8, 2001, pp. 1352-1357. http://dx.doi.org/10.1086/323334 [23] Y. Almog, A. Shefer, V. Novack, N. Maimon, L. Barski, et al., “Prior Statin Therapy Is Associated with a De- creased Rate of Severe Sepsis,” Circulation, Vol. 110, 2004, pp. 880-885. http://dx.doi.org/10.1161/01.CIR.0000138932.17956.F1 [24] R. Gupta, L. C. Plantinga, N. E. Fink, M. L. Melamed, J. Coresh, et al., “Statin Use and Hospitalization for Sepsis in Patients with Chronic Kidney Disease,” JAMA, Vol. 297, No. 13, 2007, pp. 1455-1464. http://dx.doi.org/10.1001/jama.297.13.1455 [25] E. M. Van De Garde, E. Hak, P. C. Souverein, A. W. Hoes, J. M. van den Bosch and H. G. Leufkens, “Statin Treatment and Reduced Risk of Pneumonia in Patients with Diabetes.” [26] P. Kruger, K. Fitzsimmons, D. Cook, M. Jones and G. Nimmo, “Statin Therapy Is Associated with Feder Deaths in Patients with Bacteraemia,” Intensive Care Medicine, Vol. 32, No. 1, 2006, pp. 75-79. http://dx.doi.org/10.1007/s00134-005-2859-y [27] D. G. Hackam, M. Mandami, P. Li and D. A. Redelmeier, “Statins and Sepsis in Patients with Cardiovascular Dis- ease: A Population-Based Cohort Analysis,” Lancet, Vol. 367, No. 9508, 2006, pp. 413-418. http://dx.doi.org/10.1016/S0140-6736(06)68041-0 [28] Y. Almog, V. Novack, M. Eisinger, A. Porath, L. Novack, et al., “The Effect of Statin Therapy on Infection-Related Mortality in Patients with Atherosclerotic Diseases,” Cri- tical Care Medicine, Vol. 35, No. 2, 2007, pp. 372-378. http://dx.doi.org/10.1097/01.CCM.0000253397.42079.D5 [29] C. P. Martin, R. L. Talbert, D. S. Burgess and J. I. Peters, “Effectiveness of Statins in Reducing the Rate of Severe Sepsis: A Retrospective Evaluation,” Pharmacotherapy, Vol. 27, No. 1, 2007, pp. 20-26. [30] P. Kruger, K. Fitzsimmons, D. Cook, M. Jones and G. Nimmo, “Statin Therapy Is Associated with Fewer Deaths in Patients with Bacteraemia,” Intensive Care Medicine, Vol. 32, No. 1, 2006, pp. 75-79. http://dx.doi.org/10.1007/s00134-005-2859-y [31] E. M. Mortensen, M. I. Restrepo, A. Anzueto and J. Pugh, “The Effect of Prior Statin Use on 30-Day Mortality for Patients Hospitalized with Community-Acquired Pneu- monia,” Respiratory Research, Vol. 6, 2005, p. 82. http://dx.doi.org/10.1186/1465-9921-6-82 [32] H. Schmidt, R. Hennen, A. Keller, et al., “Association of Statin Therapy and Increased Survival in Patients with Multiple Organ Dysfunction Syndrome,” Intensive Care Medicine, Vol. 32, No. 8, 2006, pp. 1248-1251. http://dx.doi.org/10.1007/s00134-006-0246-y [33] S. Al Harbi, H. M. Tamim and Y. N. Marabi, “Associa- tion between Statin Therapy and Outcomes in Critically Ill Patients: A Nested Cohorte Study,” BMC Clinical Pharmacology, Vol. 11, 2011, p. 12. http://dx.doi.org/10.1186/1472-6904-11-12 [34] F. J. Frost, H. Petersen, K. Tollestrup and B. Skipper, “Influenza and COPD Mortality Protection as Pleiotropic, Dose-Dependent Effects of Statins,” Chest, Vol. 131, No. 4, 2007, pp. 1006-1012. http://dx.doi.org/10.1378/chest.06-1997 [35] R. G. Schielenger, D. S. Fedson, S. S. Jick, H. Jick and C. R. Meier, “Statins and the Risk of Pneumonia: A Popula- tion-Based, Nested Case-Control Study,” Pharmacother- apy, Vol. 27, No. 3, 2007, pp. 325-332. [36] D. Viasus, D. Gudiol, N. Fernández-Sabé, I. Cabello, G. García-Vidal, et al., “Effect of Statins on Outcomes in Inmunosuppressed Patients with Bloodstream Infections,” European Journal of Clinical Microbiology & Infectious Diseases, Vol. 30, No. 1, 2011, pp. 77-82. http://dx.doi.org/10.1007/s10096-010-1056-2 [37] R. Fernandez, V. J. De Pedro and A. Artigas, “Statin Therapy Prior to ICU Admisión: Protection against Infec- tion or a Severity Marker?” Intensive Care Medicine, Vol. 32, No. 1, 2006, pp. 160-164. http://dx.doi.org/10.1007/s00134-005-2743-9 [38] K. C. Yang, J. Y. Chien, W. K. Tseng, P. R. Hsueh, C. J. Yu and C. C. Wu, “Statins Do Not Improve Short-Term Survival in an Oriental Population with Sepsis,” Ameri- can Journal of Emergency Medicine, Vol. 25, No. 5, 2007, pp. 494-501. http://dx.doi.org/10.1016/j.ajem.2006.09.011 [39] P. Kopterides, M. E. Falagas, “Statins for Sepsis: A Criti- cal and Updated Review,” Clinical Microbiology and In- fection, Vol. 15, No. 4, 2009, pp. 325-334. http://dx.doi.org/10.1111/j.1469-0691.2009.02750.x [40] G. N. Forrest, A. M. Kopack and E. N. Perencevich, “Statins in Candidemia: Clinical Outcomes from a Matched Cohort Study,” BMC Infectious Diseases, Vol. 10, 2010, p. 152. http://dx.doi.org/10.1186/1471-2334-10-152 [41] H. Y. Sun and N. Singh, “Antimicrobial and Immuno- Open Access PP
Statins and Sepsis Literature Review Open Access PP 577 modulatory Attributes of Statins: Relevante in Solid-Or- gan Transplant Recipients,” Clinical Infectious Diseases, Vol. 48, No. 6, 2009, pp. 745-755. http://dx.doi.org/10.1086/597039 [42] K. Haldar, “Targeting the Host to Control an Infection Disorder,” Archives of Internal Medicine, Vol. 168, No. 19, 2008, pp. 2067-2068. http://dx.doi.org/10.1001/archinte.168.19.2067 [43] P. S. Kruger, N. M. Freir, B. Venkatesh, T. A. Robertson, M. S. Roberts, et al., “A Preliminary Study of Atorvas- tatin Plasma Concentrations in Critically Ill Patients with Sepsis,” Intensive Care Medicine, Vol. 35, No. 4, 2009, pp. 717-721. http://dx.doi.org/10.1007/s00134-008-1358-3 [44] S. Christensen, R. W. Thomsen, M. B. Johansen, L. Pe- dersen, R. Jensen, et al., “Preadmission Statin Use and One-Year Mortality among Patients in Intensive Care—A Cohorte Study,” Critical Care, Vol. 14, No. 2, 2010, p. R29. [45] S. R. Majumdar, F. A. McAlister, D. T. Eurich, R. S. Padwal and T. J. Marrie, “Statins and Outcomes in Pa- tients Admitted to Hospital with Community Acquired Pneumonia: Population Based Prospective Cohort Study,” BMJ, Vol. 333, 2006, p. 999. http://dx.doi.org/10.1136/bmj.38992.565972.7C
|